Bioasis Announces Stock Option Grants
30 August 2019 - 6:05AM
Business Wire
BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a
pre-clinical, research-stage biopharmaceutical company developing
its proprietary xB3 TM platform technology for the delivery of
therapeutics across the blood-brain barrier (“BBB”) and the
treatment of central nervous system (“CNS”) disorders in areas of
high unmet medical need, including brain cancers and
neurodegenerative diseases, today announced that it has granted
stock options to acquire a total of 875,000 common shares at a
price of $0.32 per share to directors of the company. The directors
have agreed to receive a portion of their compensation in stock
options. All of the options vest over a period of 12 months from
the date of grant, expire five years from the date of the grant and
are governed by the terms of the company’s stock option plan.
About Bioasis
Bioasis Technologies Inc. is a biopharmaceutical company
developing the xB3 TM platform, a proprietary technology for the
delivery of therapeutics across the blood brain barrier and the
treatment of CNS disorders in areas of high unmet medical need,
including brain cancers and neurodegenerative diseases. The
delivery of therapeutics across the blood brain barrier represents
the final frontier in treating neurological disorders. The in-house
development programs at Bioasis are designed to develop symptomatic
and disease-modifying treatments for brain-related diseases and
disorders. The company maintains headquarters in Guilford, Conn.,
United States. Bioasis trades on the TSX Venture Exchange under the
symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more
information about the company, please visit www.bioasis.us.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190829005700/en/
Deborah Rathjen, Ph.D., Executive Chair deborah@bioasis.us +1
203 533 7082
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Jan 2025 to Feb 2025
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Feb 2024 to Feb 2025